

Ticker: [VTRS US EQUITY](#)

**Viatrix Inc (NASDAQ GS: VTRS, Currency: USD)**

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Website	www.viatrix.com/en
Number of Employees	37,000
Ticker:	VTRS US


1000 Mylan Blvd Canonsburg, PA 15317 United States
Phone : 1-724-514-1800
Fax : --

↑ **10.73** +0.08 (0.75%)

Viatrix Inc. opera como una empresa farmacéutica. Produce medicamentos para pacientes en varias áreas terapéuticas principales que abarcan enfermedades no transmisibles e infecciosas. Atiende a pacientes en todo el mundo.

Stock Quote & Chart (Currency: USD)			
Last (delayed quote)	10.73	Market Cap (MM)	12,872.5
Open	10.66	Shares Out. (MM)	1,199.7
Previous Close	10.65	Float %	99.6%
Change	0.00	Shares sold short (MM)	32,325,234.0
Change %	0.00	Dividend Yield %	4.5
Day High/Day Low	10.7 / 10.6	Diluted EPS Excl. XO	
52 Wk High/52 Wk low	12.4 / 8.7	P / Diluted EPS Before XO	
Volume (MM)	2.77	Beta	0.97
Avg. Vol - 3 mo (MM)	8.97		

Financial Information (Currency: USD, in mm)			
Revenue - LTM	15,465.6	Cash & ST Invest.	1,295
EBIT - LTM	1,019.4	Total Assets	50,022.2
EBITDA - LTM	3,985.3	Total Debt	19,536.3
Net Income - LTM	1,831.5	Total Liabilities	28,949.9
Total Enterprise Value	30,161	Total Equity	21,072.3
TEV/ Total Revenue	1.9 x	Cash from Operations - LTM	2,462.8
TEV/ EBITDA	7.3 x	Cash From Investing - LTM	904.6
		Cash from Financing -LTM	-2,706.0



Company Notes	
	A gain of \$20.200 from Legal Expense
	A gain of \$67.800 from Sale of Investments
	2014 Q4
	GAAP Net Income Includes: (in millions, pre-tax)
	A gain of \$2.400 from Sale of Business
	A gain of \$67.800 from Sale of Investments
	2014 Q1
	GAAP Net Income includes, (in millions, pre-tax):
	a gain of \$20.200 from Legal/Litigation/Settlement
	2013 A1
	GAAP Net Income Includes: (in millions, pre-tax)
	A loss of \$2,784.100 from Legal Expense
	A gain of \$81.100 from Sale of Business
	2013 Q4
	GAAP Net Income Includes: (in millions, pre-tax)
	A loss of \$2,784.100 from Legal Expense
	A gain of \$-45.900 from Sale of Business
	2013 Q2
	GAAP Net Income Includes: (in millions, pre-tax)
	A gain of \$35.200 from Sale of Business
	2011 A1
	GAAP Net Income includes, (in millions, pre-tax):
	a gain of \$30.200 from Sale of Properties

Key Board Members			
Name	Title	Organization	
1 W Don Cornwell	Co-Founder	Granite Broadcasting Corp	
2	Board Member	Viatrix Inc	
3	Board Member	American Intl Group Inc	
4	Trustee	Edna Mcconnell Clark Foundatio	
5 James Marshall Kilts "Jim"	Founding Partner	Centerview Partners	
6	Founding Partner/Co-Founder	Centerview Capital Holdings LI	
7	Chairman	Advantage Solutions Inc	
8	Board Member	Viatrix Inc	
9	Chairman	Simply Good Foods Co/The	
#	Trustee	University Of Chicago	
#	Board Member	Cato Inst	
# Elisha W Finney	Board Member	Viatrix Inc	
#	Board Member	Mettler-Toledo Intl Inc	
#	Board Member	Nanostring Technologies Inc	
#	Board Member	Icu Medical Inc	
# Harry A Korman "Hal"	Board Member	Viatrix Inc	
# Joellen Lyons Dillon	Board Member	Viatrix Inc	
# Melina E Higgins	Chairman	Antares Capital Corp	
#	Chairman	Antares Capital Lp	
#	Chair	Viatrix Inc	
#	Chairman	Genworth Financial Inc	
# Mark W Parrish	Senior Advisor	Frazier Management Llc	
#	President/Ceo	Intl Federation Of Pharmacutca	
#	Chairman	Safecor Health Llc	
#	Vice Chairman	Viatrix Inc	
#	Board Member	Omicell Inc	
#	Board Member	Comprehensive Pharmacy Svcs	
#	Board Member	Silvagate Pharmaceuticals Inc	
# Rajiv Malik	President/Executive Director	Viatrix Inc	

Ticker: **VTRS US EQUIT**

**Viatris Inc**


Period Type: **Annuals**

Sector: **Salud** Industry: **Productos farmacéuticos** Sub-Industry: **Productos farmacéuticos**

Annuals	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0FQ	1FY	2FY	3FY
<b>Key Financials</b>											
	Actuals						LTM	Estimates			
For the Fiscal Period Ending	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	30/09/2023	30/09/2023	31/12/2023	31/12/2024	31/12/2025
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
<b>Total Revenue</b>	11,076.9	11,907.7	11,433.9	11,500.5	11,946.0	17,886.3	16,262.7	3,941.9	16,262.7	3,861.6	3,861.6
<i>Growth Over Prior Year</i>	17.5%	7.5%	(4.0%)	0.6%	3.9%	49.7%	(9.1%)	(7.5%)	(0.4%)	(0.4%)	(0.4%)
<b>Gross Profit</b>	4,697.0	4,783.1	4,001.6	3,897.6	3,796.7	5,575.5	6,497.0	6,116.2	--	--	--
<i>Margin %</i>	42.4%	40.2%	35.0%	33.9%	31.8%	31.2%	40.0%	155.2%	--	--	--
<b>EBITDA</b>	2,224.6	3,242.9	3,015.5	2,822.4	2,086.0	4,570.1	4,733.4	3,985.3	1,213.8	1,213.8	1,213.8
<i>Margin %</i>	20.1%	27.2%	26.4%	24.5%	17.5%	25.6%	29.1%	101.1%	7.5%	31.4%	31.4%
<b>EBIT</b>	701.6	1,437.1	905.6	715.5	(210.8)	(34.0)	1,614.9	1,019.4	1,095.2	1,095.2	1,095.2
<i>Margin %</i>	6.3%	12.1%	7.9%	6.2%	(1.8%)	(0.2%)	9.9%	25.9%	6.7%	28.4%	28.4%
<b>Earnings from Cont. Ops.</b>	480.0	696.0	352.5	16.8	(669.9)	(1,269.1)	2,078.6	1,831.5	--	--	--
<i>Margin %</i>	4.3%	5.8%	3.1%	0.1%	(5.6%)	(7.1%)	12.8%	46.5%	--	--	--
<b>Net Income</b>	480.0	696.0	352.5	16.8	(669.9)	(1,269.1)	2,078.6	1,831.5	781.0	781.0	781.0
<i>Margin %</i>	4.3%	5.8%	3.1%	0.1%	(5.6%)	(7.1%)	12.8%	46.5%	4.8%	20.2%	20.2%
<b>Diluted EPS Excl. Extra Items</b>	0.9	1.3	0.7	0.0	(1.1)	(1.1)	1.7	1.5	0.6	0.6	0.6
<i>Growth Over Prior Year</i>	(45.9%)	41.3%	(47.7%)	(95.6%)	--	5.4%	--	128.8%	(22.0%)	(22.0%)	(22.0%)

**Current Capitalization (Millions)**

Currency	USD
Share Price (USD)	10.73
Shares Out.	1,199.67
<b>Market Capitalization (USD)</b>	<b>12,872.47</b>
- Cash & Short Term Investments	1,344.70
+ Total Debt	18,633.30
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
<b>= Total Enterprise Value (USD)</b>	<b>30,161.07</b>
Book Value of Common Equity	20,865.60
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
+ Total Debt	18,633.30
<b>= Total Capital</b>	<b>39,498.90</b>




**Valuation Multiples based on Current Capitalization**

For the Fiscal Period Ending	Actual	LTM	Estimates	
	30/09/2023	30/09/2023	30/09/2023	30/09/2023
TEV/Total Revenue	2.0x	1.9x	7.6x	7.6x
TEV/EBITDA	6.7x	7.3x	5.7x	5.7x
TEV/EBIT	19.6x	28.6x	6.3x	6.3x
P/Diluted EPS Before Extra	6.5x	6.5x		
P/BV	0.6x	0.6x	0.6x	0.6x
Price/Tang BV	--	--		

**Valuation Multiples for Chart**

For the Fiscal Period Ending	TTM	FY1	NTM	FY2
PE Ratio	7.3x	3.8x	3.8x	3.8x
TEV / EBITDA	7.3x	5.7x	5.7x	5.7x
Price / CF	5.2x	1.3x	1.3x	1.3x
Price / Book	0.6x	0.6x	0.6x	0.6x
Dividend Yield	4.5x	4.8x	4.8x	4.8x

**PE Ratio**



Ticker:	VTRS US EQUITY
Period Type	Annuals

VTRS US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

## Viatrix Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY
<b>Income Statement</b>											
<b>Income Sheet as of:</b>											
<b>Currency</b>	31/12/2012 USD	31/12/2013 USD	31/12/2014 USD	31/12/2015 USD	31/12/2016 USD	31/12/2017 USD	31/12/2018 USD	31/12/2019 USD	31/12/2020 USD	31/12/2021 USD	31/12/2022 USD
Revenue	6,750.20	6,856.60	7,646.50	9,362.60	10,967.10	11,760.00	11,268.70	11,370.30	11,819.90	17,813.60	16,218.10
Other Revenue	45.90	52.50	73.10	66.70	109.80	147.70	165.20	130.20	126.10	72.70	44.60
<b>Total Revenue</b>	<b>6,796.10</b>	<b>6,909.10</b>	<b>7,719.60</b>	<b>9,429.30</b>	<b>11,076.90</b>	<b>11,907.70</b>	<b>11,433.90</b>	<b>11,500.50</b>	<b>11,946.00</b>	<b>17,886.30</b>	<b>16,262.70</b>
Cost Of Goods Sold	3,887.80	3,868.80	4,191.60	5,213.20	6,379.90	7,124.60	7,432.30	7,602.90	8,149.30	12,310.80	9,765.70
<b>Gross Profit</b>	<b>2,908.30</b>	<b>3,040.30</b>	<b>3,528.00</b>	<b>4,216.10</b>	<b>4,697.00</b>	<b>4,783.10</b>	<b>4,001.60</b>	<b>3,897.60</b>	<b>3,796.70</b>	<b>5,575.50</b>	<b>6,497.00</b>
Selling General & Admin Exp.	1,397.60	1,397.00	1,593.60	2,083.30	3,168.60	2,562.70	2,391.50	2,542.20	3,452.40	4,858.40	4,183.50
R & D Exp.	401.30	507.80	581.80	671.90	826.80	783.30	704.50	639.90	555.10	751.10	662.20
Depreciation & Amort.	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	36.40
<b>Operating Expense, Total</b>	<b>1,798.90</b>	<b>1,904.80</b>	<b>2,175.40</b>	<b>2,755.20</b>	<b>3,995.40</b>	<b>3,346.00</b>	<b>3,096.00</b>	<b>3,182.10</b>	<b>4,007.50</b>	<b>5,609.50</b>	<b>4,882.10</b>
<b>Operating Income</b>	<b>1,109.40</b>	<b>1,135.50</b>	<b>1,352.60</b>	<b>1,460.90</b>	<b>701.60</b>	<b>1,437.10</b>	<b>905.60</b>	<b>715.50</b>	<b>(210.80)</b>	<b>(34.00)</b>	<b>1,614.90</b>
Interest Expense	308.70	313.30	333.20	339.40	454.80	534.60	542.30	517.30	497.80	636.20	592.40
Interest Income	-	-	-	-	-	-	-	-	-	-	-
<b>Net Interest Exp.</b>	<b>308.70</b>	<b>313.30</b>	<b>333.20</b>	<b>339.40</b>	<b>454.80</b>	<b>534.60</b>	<b>542.30</b>	<b>517.30</b>	<b>497.80</b>	<b>636.20</b>	<b>592.40</b>
Currency Exchange Gains (Loss)	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	(3.50)	74.90	44.90	206.10	125.10	(0.50)	64.90	43.80	12.60	(5.80)	(1,790.70)
<b>EBT Excl. Unusual Items</b>	<b>804.20</b>	<b>747.30</b>	<b>974.50</b>	<b>915.40</b>	<b>121.70</b>	<b>903.00</b>	<b>298.40</b>	<b>154.40</b>	<b>(721.20)</b>	<b>(664.40)</b>	<b>2,813.20</b>
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-	-	-	-	-	-	-
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	-	-	-	-	-	-	-	-	-	-	-
Other Unusual Items	-	-	-	-	-	-	-	-	-	-	-
<b>EBT Incl. Unusual Items</b>	<b>804.20</b>	<b>747.30</b>	<b>974.50</b>	<b>915.40</b>	<b>121.70</b>	<b>903.00</b>	<b>298.40</b>	<b>154.40</b>	<b>(721.20)</b>	<b>(664.40)</b>	<b>2,813.20</b>
Income Tax Expense	161.20	120.80	41.40	67.70	(358.30)	207.00	(54.10)	137.60	(51.30)	604.70	734.60
<b>Earnings from Cont. Ops.</b>	<b>643.00</b>	<b>626.50</b>	<b>933.10</b>	<b>847.70</b>	<b>480.00</b>	<b>696.00</b>	<b>352.50</b>	<b>16.80</b>	<b>(669.90)</b>	<b>(1,269.10)</b>	<b>2,078.60</b>
Extraord. Item & Account. Change	-	-	-	-	-	-	-	-	-	-	-
Minority Int. in Earnings	2.10	2.80	3.70	0.10	-	-	-	-	-	-	-
<b>Net Income</b>	<b>640.90</b>	<b>623.70</b>	<b>929.40</b>	<b>847.60</b>	<b>480.00</b>	<b>696.00</b>	<b>352.50</b>	<b>16.80</b>	<b>(669.90)</b>	<b>(1,269.10)</b>	<b>2,078.60</b>
Pref. Dividends	-	-	-	-	-	-	-	-	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
<b>NI to Common Incl Extra Items</b>	<b>640.90</b>	<b>623.70</b>	<b>929.40</b>	<b>847.60</b>	<b>480.00</b>	<b>696.00</b>	<b>352.50</b>	<b>16.80</b>	<b>(669.90)</b>	<b>(1,269.10)</b>	<b>2,078.60</b>
Abnormal Losses (Gains)	234.80	328.46	413.00	744.70	1,543.90	629.60	742.90	820.00	1,618.60	1,992.30	(568.10)
Tax Effect on Abnormal Items	(76.56)	(103.79)	(110.84)	(170.02)	(439.11)	(114.69)	(185.76)	57.21	(89.95)	742.12	377.07
<b>NI to Common Excl. Extra Items</b>	<b>799.14</b>	<b>848.37</b>	<b>1,151.56</b>	<b>1,422.28</b>	<b>1,584.79</b>	<b>1,210.91</b>	<b>909.64</b>	<b>894.01</b>	<b>858.75</b>	<b>1,465.32</b>	<b>1,887.57</b>
<b>Per Share Items</b>											
Basic EPS	1.54	1.63	2.49	1.80	0.94	1.30	0.69	0.03	(1.11)	(1.05)	1.71
Basic EPS Excl. Extra Items	1.54	1.63	2.49	1.80	0.94	1.30	0.69	0.03	(1.11)	(1.05)	1.71
Weighted Avg. Basic Shares Out.	415.20	383.30	373.70	472.20	513.00	534.50	514.50	515.70	601.20	1,208.80	1,212.10
Diluted EPS	1.52	1.58	2.34	1.70	0.92	1.30	0.68	0.03	(1.11)	(1.05)	1.71
Diluted EPS Excl. Extra Items	1.52	1.58	2.34	1.70	0.92	1.30	0.68	0.03	(1.11)	(1.05)	1.71
Weighted Avg. Diluted Shares Out.	420.20	394.50	398.00	497.40	520.50	536.70	516.50	516.50	601.20	1,208.80	1,217.40
Normalized Basic EPS	2.59	2.89	3.56	4.30	4.89	4.56	4.58	4.42	3.95	3.70	1.71
Normalized Diluted EPS	1.90	2.15	2.90	2.86	3.04	2.26	1.76	1.73	1.43	1.21	1.55
Dividends per Share	-	-	-	-	-	-	-	-	-	-	-
Payout Ratio %	-	-	-	-	-	-	-	-	-	-	27.99
<b>Supplemental Items</b>											
EBITA	1,495.80	1,499.20	1,746.40	2,306.90	1,965.20	2,955.30	2,736.00	2,566.30	1,796.30	4,060.60	4,383.90
EBIT	1,109.40	1,135.50	1,352.60	1,460.90	701.60	1,437.10	905.60	715.50	(210.80)	(34.00)	1,614.90
As Reported Total Revenue*	6,796.10	6,909.10	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30	16,262.70
Effective Tax Rate %	20.04	16.16	4.25	7.40	-	22.92	-	89.12	-	-	26.11
Normalized Net Income	799.14	848.37	1,151.56	1,422.28	1,584.79	1,210.91	909.64	894.01	858.75	1,465.32	1,887.57
Interest Capitalized	-	-	-	-	-	-	-	-	-	-	-
<b>Supplemental Operating Expense Items</b>											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	42.60	47.00	66.00	92.80	88.90	74.70	(3.30)	56.80	79.20	111.20	116.40
<b>Stock-Based Comp., Total</b>	<b>42.60</b>	<b>47.00</b>	<b>66.00</b>	<b>92.80</b>	<b>88.90</b>	<b>74.70</b>	<b>(3.30)</b>	<b>56.80</b>	<b>79.20</b>	<b>111.20</b>	<b>116.40</b>

Ticker:	VTRS US EQUITY
Period Type	Annuals

VTRS US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

## Viatrix Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
<b>Balance Sheet</b>											
Balance Sheet as of:	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
<b>ASSETS</b>											
Cash And Equivalents	349.97	291.30	225.50	1,236.00	998.80	292.10	388.10	475.60	844.40	701.20	1,259.90
Short Term Investments	-	-	-	-	83.70	76.70	25.00	26.80	39.10	38.20	35.30
<b>Total Cash &amp; ST Investments</b>	<b>349.97</b>	<b>291.30</b>	<b>225.50</b>	<b>1,236.00</b>	<b>1,082.50</b>	<b>368.80</b>	<b>413.10</b>	<b>502.40</b>	<b>883.50</b>	<b>739.40</b>	<b>1,295.20</b>
Accounts & Notes Receivable	1,554.34	1,820.00	2,268.50	2,689.10	3,015.40	3,173.10	2,416.50	2,640.10	3,891.30	3,774.40	3,243.80
<b>Total Receivables</b>	<b>1,554.34</b>	<b>1,820.00</b>	<b>2,268.50</b>	<b>2,689.10</b>	<b>3,015.40</b>	<b>3,173.10</b>	<b>2,416.50</b>	<b>2,640.10</b>	<b>3,891.30</b>	<b>3,774.40</b>	<b>3,243.80</b>
Inventories	1,525.24	1,656.90	1,651.40	1,951.00	2,456.40	2,542.70	2,580.20	2,670.90	5,471.90	3,977.70	3,519.50
Prepaid Exp.	243.82	452.90	2,295.80	596.60	756.40	766.10	518.40	552.00	1,707.40	1,957.60	1,811.20
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	229.35	250.10	-	-	211.80	362.60	439.50	391.90	913.40	453.80	765.70
<b>Total Current Assets</b>	<b>3,902.72</b>	<b>4,471.20</b>	<b>6,441.20</b>	<b>6,472.70</b>	<b>7,522.50</b>	<b>7,213.30</b>	<b>6,367.70</b>	<b>6,757.30</b>	<b>12,867.50</b>	<b>10,902.90</b>	<b>10,635.40</b>
<b>Net Property, Plant &amp; Equipment</b>	<b>1,397.22</b>	<b>1,665.50</b>	<b>1,785.70</b>	<b>1,983.90</b>	<b>2,322.20</b>	<b>2,339.10</b>	<b>2,170.20</b>	<b>2,404.20</b>	<b>3,783.50</b>	<b>3,479.40</b>	<b>3,283.80</b>
Long-term Investments	-	-	-	-	-	-	-	-	-	-	-
Deferred Charges, LT	87.66	77.80	397.40	457.60	633.20	496.80	572.20	703.10	2,147.90	1,332.70	925.90
Other Long-Term Assets	6,544.31	9,080.30	7,196.20	13,353.50	24,248.30	25,757.10	23,624.80	21,390.90	42,754.10	39,127.80	35,177.10
<b>Total Assets</b>	<b>11,931.90</b>	<b>15,294.80</b>	<b>15,820.50</b>	<b>22,267.70</b>	<b>34,726.20</b>	<b>35,806.30</b>	<b>32,734.90</b>	<b>31,255.50</b>	<b>61,553.00</b>	<b>54,842.80</b>	<b>50,022.20</b>
<b>LIABILITIES</b>											
Accrued Exp.	-	-	-	-	-	-	-	-	-	-	-
Short-term Borrowings	397.04	443.40	2,803.60	1,078.30	336.40	1,855.40	701.70	1,584.80	3,502.30	3,457.20	1,339.70
Accounts Payable	777.91	1,072.80	905.60	1,109.60	1,348.10	1,452.50	1,617.00	1,528.10	1,904.20	1,657.40	1,766.60
Curr. Income Taxes Payable	33.73	49.70	160.70	92.40	97.70	112.90	121.50	213.00	288.60	236.90	279.60
Other Current Liabilities	984.83	1,398.10	1,434.10	1,841.90	3,258.50	2,964.50	2,147.60	2,243.20	4,867.80	4,532.90	3,360.30
<b>Total Current Liabilities</b>	<b>2,193.50</b>	<b>2,964.00</b>	<b>5,304.00</b>	<b>4,122.20</b>	<b>5,040.70</b>	<b>6,385.30</b>	<b>4,587.80</b>	<b>5,569.10</b>	<b>10,562.90</b>	<b>9,884.40</b>	<b>6,746.20</b>
Long-Term Debt	4,700.90	7,586.50	3,846.40	6,295.60	15,202.90	12,865.30	13,161.20	11,390.00	22,658.70	19,918.00	18,196.60
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	1,681.67	1,784.40	3,394.10	2,084.10	3,365.00	3,248.10	2,818.80	2,412.60	5,377.30	4,547.70	4,007.10
<b>Total Liabilities</b>	<b>8,576.07</b>	<b>12,334.90</b>	<b>12,544.50</b>	<b>12,501.90</b>	<b>23,608.60</b>	<b>22,498.70</b>	<b>20,567.80</b>	<b>19,371.70</b>	<b>38,598.90</b>	<b>34,350.10</b>	<b>28,949.90</b>
Pref. Stock, Non-Redeem.	-	-	-	-	-	-	-	-	-	-	-
<b>Total Pref. Equity</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Minority Interest	15.11	18.10	20.10	1.40	1.40	-	-	-	-	-	-
Additional Paid In Capital	4,256.58	4,375.60	4,486.10	7,134.10	8,505.30	8,592.00	8,597.40	8,649.60	18,450.90	18,548.20	18,657.90
Retained Earnings	2,061.37	2,685.10	3,614.50	4,462.10	4,942.10	5,644.50	6,010.70	6,031.10	5,361.20	3,688.80	5,175.60
Treasury Stock	(2,890.73)	(3,878.80)	(3,857.70)	(67.50)	(67.50)	(567.70)	(999.70)	(999.70)	-	-	-
Comprehensive Inc. and Other	(86.50)	(240.10)	(987.00)	(1,764.30)	(2,263.70)	(361.20)	(1,441.30)	(1,797.20)	(858.00)	(1,744.30)	(2,761.20)
<b>Total Common Equity</b>	<b>3,355.83</b>	<b>2,959.90</b>	<b>3,276.00</b>	<b>9,765.80</b>	<b>11,117.60</b>	<b>13,307.60</b>	<b>12,167.10</b>	<b>11,883.80</b>	<b>22,954.10</b>	<b>20,492.70</b>	<b>21,072.30</b>
<b>Total Equity</b>	<b>3,355.83</b>	<b>2,959.90</b>	<b>3,276.00</b>	<b>9,765.80</b>	<b>11,117.60</b>	<b>13,307.60</b>	<b>12,167.10</b>	<b>11,883.80</b>	<b>22,954.10</b>	<b>20,492.70</b>	<b>21,072.30</b>
<b>Total Liabilities And Equity</b>	<b>11,931.90</b>	<b>15,294.80</b>	<b>15,820.50</b>	<b>22,267.70</b>	<b>34,726.20</b>	<b>35,806.30</b>	<b>32,734.90</b>	<b>31,255.50</b>	<b>61,553.00</b>	<b>54,842.80</b>	<b>50,022.20</b>
<b>Supplemental Items</b>											
Total Shares Out. on Filing Date	395.21	371.60	375.22	490.62	535.33	524.21	515.80	516.15	1,206.90	1,209.51	1,213.79
Total Shares Out. on Balance Sheet Date	395.21	371.60	375.22	490.62	535.33	524.21	515.80	516.15	1,206.90	1,209.51	1,213.79
Book Value/Share	8.45	7.92	8.68	19.90	20.77	25.39	23.59	23.02	19.02	16.94	17.36
Tangible Book Value	(2,399.39)	(3,916.60)	(3,140.50)	(2,837.60)	(12,563.50)	(12,143.90)	(11,245.30)	(9,356.70)	(19,076.10)	(17,755.20)	(11,960.60)
Tangible Book Value/Share	(6.07)	(10.54)	(8.37)	(5.78)	(23.47)	(23.17)	(21.80)	(18.13)	(15.81)	(14.68)	(9.85)
Total Debt	5,097.93	8,029.90	6,650.00	7,373.90	15,539.30	14,720.70	13,862.90	12,974.80	26,161.00	23,375.20	19,536.30
Net Debt	4,747.96	7,738.60	6,424.50	6,137.90	14,456.80	14,351.90	13,449.80	12,472.40	25,277.50	22,635.80	18,241.10
Total Minority Interest	15.11	18.10	20.10	1.40	1.40	-	-	-	-	-	-
Inventory Method	--	--	--	--	--	--	--	--	--	--	--
Raw Materials in Inventory	455.96	482.80	549.50	592.40	783.40	895.50	955.70	886.80	958.40	922.40	571.50
Work in Progress Inventory	268.19	310.00	298.40	387.00	436.00	384.70	369.90	417.20	1,438.10	993.30	755.40
Finished Goods Inventory	801.09	864.10	803.50	971.60	1,237.00	1,262.50	1,254.60	1,366.90	3,075.40	2,062.00	2,192.60
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	23.04	24.60	25.70	33.60	59.00	75.30	98.20	72.80	159.90	154.50	114.70
Full Time Employees	-	20,000.00	30,000.00	35,000.00	35,000.00	35,000.00	35,000.00	35,000.00	45,000.00	37,000.00	37,000.00











Ticker: **VTRS US EQUITY**      **VTRS US EQUITY** Ascend      Currency  Reporting  Change      **USD**

Period Type: **Annuals**      Consolidated: **Yes**      Accounting: **Mixed**

**Viatrix Inc**

Sector: Salud    Industry: Productos farmacéuticos    Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022
<b>REVENUE</b>											
<b>Revenue by Product</b>											
For the Fiscal Period Ending											
Revenue	6,796.10	6,909.10	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30	16,262.70
Brands	5,946.20	5,900.70	6,510.40	9,429.30	10,967.10	11,760.00	11,268.70	5,362.10	5,289.50	10,841.30	9,889.60
Generics	849.90	1,008.50	51.10	-	109.80	-	165.20	4,796.90	5,234.90	5,630.20	5,015.10
Complex Generics & Biosimilars	-	-	-	-	-	-	-	1,211.30	1,295.50	1,342.10	1,313.40
Other Sources	-	-	-	-	-	-	-	-	126.10	72.70	44.60
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-

Revenue by Geography	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022
For the Fiscal Period Ending											
Revenue	6,796.10	6,909.10	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30	16,262.70
Developed Markets	4,060.70	3,988.30	4,548.40	5,100.40	5,629.50	4,969.60	4,157.30	-	8,510.90	10,428.70	9,768.90
Emerging Markets	1,391.90	1,438.60	1,621.30	2,205.60	2,953.80	3,958.30	4,095.60	-	1,853.80	3,144.70	2,615.60
	1,297.60	1,429.70	1,476.80	2,056.60	2,383.80	2,832.10	3,015.80	-	1,195.30	2,212.80	2,201.20
	45.90	52.50	73.10	66.70	109.80	147.70	165.20	-	259.90	2,027.40	1,632.40
	-	-	-	-	-	-	-	-	126.10	72.70	44.60
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-

**GROSS PROFIT BEF TAX**

**OPERATING PROFIT BEF TAX**

Ticker: <b>VRTX US EQUITY</b>	Sort <b>Ascend</b>	Currency <b>USD</b>	Reporting <b>Change</b>
Period Type <b>Annuals</b>	Consolidated <b>Yes</b>	Accounting <b>Mixed</b>	

**Viatrix Inc**

Sector: **Salud** Industry: **Productos farmacéuticos** Sub-Industry: **Productos farmacéuticos**

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
<b>Pension</b>											
<b>For the Fiscal Period Ending</b>	<b>31/12/2012</b>	<b>31/12/2013</b>	<b>31/12/2014</b>	<b>31/12/2015</b>	<b>31/12/2016</b>	<b>31/12/2017</b>	<b>31/12/2018</b>	<b>31/12/2019</b>	<b>31/12/2020</b>	<b>31/12/2021</b>	<b>31/12/2022</b>
<b>Currency</b>	<b>USD</b>	<b>USD</b>	<b>USD</b>	<b>USD</b>	<b>USD</b>	<b>USD</b>	<b>USD</b>	<b>USD</b>	<b>USD</b>	<b>USD</b>	<b>USD</b>
<b>Pension Net Periodic Cost</b>											
Service Cost	--	--	5.00	11.90	17.40	20.10	19.20	20.70	23.50	38.60	32.60
Interest Cost	--	--	2.60	4.00	8.20	13.60	13.00	13.60	13.50	31.60	36.80
Expected Return on Plan Assets	--	--	(1.70)	(6.40)	(10.90)	(14.30)	(14.40)	(12.10)	(19.90)	(66.10)	(64.60)
Pension Expense (Income)	-	-	7.00	11.80	13.40	18.20	17.90	22.00	18.60	(10.20)	7.80
<b>Other Postretirement Cost</b>											
Service Cost	--	--	0.50	0.60	0.60	0.70	0.60	0.60	1.20	3.40	3.40
Interest Cost	--	--	1.00	1.10	1.30	1.60	1.50	1.50	1.40	2.60	3.70
Expected Return on Plan Assets	--	--	-	-	-	-	-	-	-	-	-
Other Postretirement Benefits Expense (I	-	-	-	-	-	-	2.30	5.50	2.90	6.20	2.90
<b>Pension Funded Status</b>											
Fair Value of Plan Assets	--	--	--	162.00	291.70	296.10	283.50	315.70	1,354.60	1,366.40	1,067.10
Actual Return (Loss) on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Employer Contribution	--	--	--	--	--	--	28.90	26.40	58.20	97.00	25.60
Benefits Paid	--	--	--	--	--	--	(24.90)	(23.90)	(24.60)	(52.80)	(54.10)
Projected Benefit Obligation	--	--	--	234.40	632.90	665.20	635.40	674.70	2,145.80	1,946.60	1,379.00
Over(Under) Funded Pension	--	--	--	(72.40)	(341.20)	(369.10)	(351.90)	(359.00)	(791.20)	(580.20)	(311.90)
Accumulated Benefit Obligation	--	--	--	--	--	--	--	--	--	--	--
Pension Funding Ratio	--	--	--	69.11	46.09	44.51	44.62	46.79	63.13	70.19	77.38
<b>Other Postretirement Funded Status</b>											
Fair Value of Plan Assets	--	--	--	-	-	-	-	-	-	-	-
Actual Return (Loss) on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Employer Contribution	--	--	--	--	--	--	2.50	9.40	1.70	18.30	10.20
Benefits Paid	--	--	(1.60)	(2.00)	(2.20)	(2.70)	(2.70)	(2.50)	(1.60)	(20.70)	(14.70)
Projected Benefit Obligation	--	--	--	--	--	--	34.00	33.80	188.80	188.40	137.50
Over(Under) Funded Post Ret Benefits	--	--	--	(26.00)	(38.00)	(35.10)	(34.00)	(33.80)	(188.80)	(188.40)	(137.50)
Other Post-Retirement Funding Ratio	--	--	--	--	--	--	-	-	-	-	-
<b>Actuarial Assumptions</b>											
<b>Pension</b>											
Expected Return on Plan Assets	--	--	--	--	--	--	4.90	4.30	4.30	5.10	5.00
Discount Rate used on Plan Liabilities	--	--	--	--	--	--	2.30	1.60	1.90	2.30	4.80
Rate of Compensation Increase	--	--	--	--	--	--	2.90	2.90	2.90	3.10	3.70
<b>Other Postretirement Benefits</b>											
Expected Return on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Discount Rate used on Plan Liabilities	--	--	--	--	--	--	3.70	4.30	3.30	1.90	2.30
Health Care Cost Trend Projected(next y	--	--	--	--	--	--	--	--	--	--	--
<b>Pension Plan Asset Allocation</b>											
Fair Value of Plan Assets	--	--	--	162.00	291.70	296.10	283.50	315.70	1,354.60	1,366.40	1,067.10
Asset Category - Equities %	--	--	--	--	--	--	43.92	28.29	45.28	40.33	37.14
Asset Category - Debt %	--	--	--	--	--	--	43.67	56.98	43.70	45.15	42.46
Asset Category - Real Estate %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Company Stock %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Cash %	--	--	--	--	--	--	1.38	1.24	3.82	4.76	3.29
Asset Category - Other %	--	--	--	--	--	--	11.04	13.49	7.19	9.76	17.11
<b>Expected Pension Payments</b>											
Year 1	--	--	--	--	--	--	32.00	33.20	104.50	101.80	93.10
Year 2	--	--	--	--	--	--	34.20	34.00	102.30	97.10	96.10
Year 3	--	--	--	--	--	--	35.70	34.70	104.90	103.00	97.90
Year 4	--	--	--	--	--	--	34.00	35.20	108.60	100.70	98.30
Year 5	--	--	--	--	--	--	36.40	38.90	106.90	104.30	102.00
Beyond Year 5	--	--	--	--	--	--	192.10	193.10	526.20	528.50	518.10
<b>Expected Postretirement Benefits</b>											
Year 1	--	--	--	--	--	--	1.70	2.00	16.40	16.10	15.40
Year 2	--	--	--	--	--	--	1.70	1.80	16.60	16.50	15.80
Year 3	--	--	--	--	--	--	2.00	1.90	16.50	16.90	15.80
Year 4	--	--	--	--	--	--	2.30	1.90	16.60	16.80	15.70
Year 5	--	--	--	--	--	--	2.20	2.00	16.30	16.60	15.10
Beyond Year 5	--	--	--	--	--	--	11.60	10.20	71.40	73.00	64.50

